News
-
Time Therapeutics Announces News Release: Preliminary Results of REBRAnD Study, an Investigator-Initiated Clinical Trial for Familial Alzheimer’s Disease by Center for iPS Cell Research and Application (CiRA), Kyoto University; Drug Repositioning of Bromocriptine”
-
Exclusive license of “Preventative or therapeutic agent for tauopathy” patent submission by Kyoto University is granted from iPS Academia Japan, Inc. (Kyoto Japan).
-
Time Therapeutics Announces News Release: Investigator-Initiated Clinical Trial for Familial Alzheimer’s Disease by Kyoto University
-
Time Therapeutics Announces Clinical Trial Agreement for Investigator-Initiated Study with Kyoto University
-
Our homepage is opened